Low-dose Interleukin-2 Therapy in Active Systemic Lupus Erythematosus (LUPIL-2): A Multicentre, Double-blind, Randomised and Placebo-controlled Phase II Trial
Ann Rheum Dis. 2022;81:1685–1694
Following evidence of associated disturbances in Treg homeostasis playing a crucial role in the pathogenesis of SLE, but no currently approved treatments that address the modulation of Treg biology, Humrich, et al. evaluate the efficacy of low-dose IL-2 therapy in patients with moderate-to-severe SLE disease activity, receiving standard treatment.